Observational studyFrontiers in immunology2025
The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study.
Observational study in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunotherapy plus targeted therapy for recurrent or metastatic head and neck squamous cell carcinoma: an updated meta-analysis and subgroup analysis by target mechanism.Frontiers in oncology · 2026Pooled it
- The microbiome-inflammation-immune axis in oral squamous cell carcinoma: from mechanistic insights to therapeutic perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) face poor prognosis. This study evaluated the efficacy and safety of a novel first-line regimen combining tislelizumab, nab-paclitaxel, carboplatin, and cetuximab (TPCE) in R/M-HNSCC. Methods: In this retrospective study, 39 patients with R/M-HNSCC received tislelizumab (200 mg, day 1), nab-paclitaxel (125 mg/m Results: The TPCE regimen demonstrated significant antitumor activity, with an ORR of 82.1% and a DCR of 97.4%. With a median follow-up of 27.0 months (95% confidence interval [CI]: 23.6-30.4 months), the median DOR was 12.5 months (95% CI: 9.5-15.5 months), the median PFS was 14.0 months (95% CI: 11.0-17.1 months), and the median OS was 27.0 months (95% CI: 20.7-33.3 months). The 2-year PFS rate was 31.3 ± 7.8%, and the 2-year OS rate was 58.4 ± 8.4%. Subgroup analysis revealed a significantly higher ORR in patients with tongue carcinoma (P = 0.023). Lower baseline neutrophil-to-lymphocyte ratio (NLR, P = 0.044), systemic immune-inflammation index (SII, P = 0.044), and albumin level (P = 0.044) were correlated with improved ORR. A reduction in NLR after two treatment cycles was also associated with higher ORR (P = 0.037). Multivariate analysis identified baseline hemoglobin-albumin-lymphocyte-platelet (HALP) score as an independent prognostic factor for PFS (HR: 2.919; 95% CI: 1.153-7.391; P = 0.024), while primary tumor location (HR: 3.160; 95% CI: 1.205-8.282; P = 0.019), HALP score (HR: 3.541; 95% CI: 1.287-9.744; P = 0.014), and post-treatment SII changes (HR: 0.370; 95% CI: 0.151-0.906; P = 0.030) were independent predictors for OS. Grade 3-4 treatment-emergent adverse events were primarily hematologic, with granulocytopenia (38.5%) being the most common. Most immune-related adverse events were grade 1-2, with hypothyroidism (33.3%) occurring most frequently. Conclusion: The TPCE regimen demonstrated robust antitumor efficacy and a manageable safety profile as a first-line treatment for R/M-HNSCC. Baseline and dynamic inflammatory-nutritional markers may serve as predictive and prognostic indicators, supporting clinical decision-making for this patient population. Clinical trial registration: http://www.chictr.org.cn, identifier ChiCTR2500108877.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.